OCT 26, 2015 8:02 AM PDT

New Immunosuppressant Drug For Autoimmune Blood Diseases Undergoing Clinical Trials

WRITTEN BY: Kara Marker
Sirolimus, an immunosuppressant drug, as recently been used in clinical trials for patients with autoimmune blood disorders. Patients benefitting from sirolumus are highly resistant or intolerant to normal corticosteroid immunosuppressive therapy. Autoimmune lymphoproliferative syndrome (ALPS) is particularly responsive to experimental sirolimus treatments. This disease is extremely rare; only 200 ALPS patients have been identified worldwide (NIH). 

ALPS is a genetic disease that inhibits the body from producing the healthy amount of lymphoctes, resulting in a chronically swollen liver, spleen, and lymph nodes (NIH). ALPS and other autoimmune blood disorders can cause anemia, uncontrolled bleeding, and infection as the immune system targets healthy hematocytes (blood cells). 
A PET scan of an ALPS patient
Corticosteroids were discovered in the 1940s and are used often for regulating inflammation in autoimmune diseases. Unfortunately, their anti-inflammatory abilities are not without long-term adverse side effects. A 2011 review in Molecular and Cellular Endocrinology described corticosteroid treatment "clinical efficacy" as "compromised by the metabolic effects of long-treatment," including osteoporosis, hypertension, and type 2 diabetes. 

To bypass these unfavorable side effects as well as provide an option for ALPS patients resistant/intolerant to corticosteroids, scientists from the Children's Hospital of Philadelphia ran a clinical trial of 30 patients between 5 and 19 years old to see how sirolimus could be used to treat ALPS. 

Sirolimus has traditionally been prescribed to prevent the rejection of kidney transplants by suppressing the immune system (MedlinePlus). ALPS patients in the clinical trial received six months of sirolimus treatment, and there was large success with participants reaching normal blood cell counts. Patients also received a check-up after two years, and there were very few recorded adverse side effects. In addition, these patients were able to stop all other steroid treatments and rely on sirolimus to keep their disease in check. 

Senior study author David Teachey, MD, looks to sirolimus as a way for young ALPS patients to achieve "an improved quality of life as they continue treatment into adulthood."

In 2012, the Children's Hospital Boston also did a sirolumus clinical trail. Riley Cerabona, a child with CLOVES syndrome, participated in the trial. CLOVES (Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevus, Scoliosis) is very rare (ClovesSyndrome.org). Watch the video below to hear her story and more about the potential of sirolimus as an immunosuppressant. 



Source: EurekAlert

 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 13, 2020
Immunology
Antibiotics Now, Inflammatory Bowel Disease Later
AUG 13, 2020
Antibiotics Now, Inflammatory Bowel Disease Later
Taking a course of antibiotics as a baby has been linked to a spiked risk of developing inflammatory bowel disease in ad ...
SEP 13, 2020
Drug Discovery & Development
Scientists Find Way to Reduce Inflammation from Vaccines
SEP 13, 2020
Scientists Find Way to Reduce Inflammation from Vaccines
Researchers from the University of Chicago have found a new way to reduce vaccine-related inflammation from adjuvants, a ...
OCT 02, 2020
Immunology
Stop the Clot: A New Antibody Treatment for Thrombosis
OCT 02, 2020
Stop the Clot: A New Antibody Treatment for Thrombosis
Blood clotting helps stem the bleeding from a wound, suppressing blood loss and stopping pathogenic microorganisms from ...
OCT 08, 2020
Immunology
Air Pollution Particles Detected in the Placenta, Immune Cells Mop Them Up
OCT 08, 2020
Air Pollution Particles Detected in the Placenta, Immune Cells Mop Them Up
Tiny, black particles much like those found in polluted air have been found in the placentas of pregnant women, as repor ...
OCT 21, 2020
Drug Discovery & Development
Experimental Vaccine Shows Promise in Halting Alzheimer's
OCT 21, 2020
Experimental Vaccine Shows Promise in Halting Alzheimer's
In a preclinical study, researchers from the Univerity of South Florida have found that a vaccine that targets neurotoxi ...
NOV 01, 2020
Cell & Molecular Biology
There's More to Neutrophil Function Than We Knew
NOV 01, 2020
There's More to Neutrophil Function Than We Knew
Neutrophils are an abundant type of white blood cell that circulate in the blood that can provide a general defense aga ...
Loading Comments...